Loading
Nanoplatforms for Cancer Theranostics / Immune Cells in Cancer · Journal article
Biomedical Photonics · July 24, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that systematizes current nanocarrier-based strategies for delivering anti-tuberculosis and photosensitizing agents to macrophages infected with or associated with M. tuberculosis. The source discusses passive and active targeting approaches, macrophage reprogramming, and photodynamic therapy as potential strategies but reports no original empirical results, effect sizes, or clinical outcome data to support practice change.
Journal article. M. tuberculosis-infected macrophages (cellular level); tuberculosis patients (disease context, not studied population).
Macrophages serve as the primary cellular reservoir for M. tuberculosis with predominantly anti-inflammatory, immunosuppressive M2 phenotype. Combined nanotherapeutic approaches integrating direct antimicrobial activity with immune modulation are proposed as promising strategies for overcoming drug resistance.
Discussion is limited to cellular and preclinical strategies; no human efficacy or safety data presented.
This review identifies conceptual strategies and engineering approaches for targeted nanotherapy delivery but provides no clinical evidence to guide current practice. Clinicians should recognize this as a framework for understanding emerging preclinical directions rather than evidence supporting a change in therapeutic approach.
This is a narrative review systematizing delivery strategies and discussing potential approaches; it raises questions about nanotherapeutic combinations rather than reporting original empirical results or clinical outcomes.
This review identifies conceptual strategies and engineering approaches for targeted nanotherapy delivery but provides no clinical evidence to guide current practice. Clinicians should recognize this as a framework for understanding emerging preclinical directions rather than evidence supporting a change in therapeutic approach.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Tuberculosis remains a leading cause of mortality among infectious diseases, with drug resistance posing a major challenge to effective treatment. Macrophages serve as the primary cellular reservoir for M. tuberculosis (MTB), which upon interaction with this pathogen may acquire a complex phenotype with predominantly anti-inflammatory, immunosuppressive properties and establish a metabolically privileged niche that supports intracellular persistence and survival of MTB. In this review, the phenotype of such macrophages is referred to as M2 (alternatively activated macrophages). This review systematizes current strategies for targeted delivery of anti-tuberculosis agents to MTB-infected macrophages using macromolecular and nanoscale carriers. Passive and active targeting approaches are examined, including the engineering of vector properties through ligand conjugation to M2 macrophage receptors. Strategies for reprogramming macrophage functional phenotype and the development of nanoscale biomimetics are discussed. Special emphasis is placed on targeted delivery of photosensitizers to infected cells for antimicrobial photodynamic therapy. The summarized evidence indicates that combined nanotherapeutic approaches, integrating direct antimicrobial activity with modulation of local immune responses, offer promising strategies for overcoming drug resistance and achieving eradication of MTB.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.